Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 67953964

Drug Profile

JNJ 67953964

Alternative Names: JNJ-3964; JNJ-67953964

Latest Information Update: 20 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Antidepressants
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 17 Dec 2019 Janssen Research & Development initiates a phase I trial in healthy volunteers in Belgium (NCT04185051)
  • 04 Dec 2019 Janssen Research & Development plans a phase I trial in healthy volunteers in Belgium in February 2020 (NCT04185051)
  • 16 Jul 2018 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT03559192)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top